Boule Diagnostics publishes the annual report for 2022

Boule Diagnostics AB has published the full Swedish annual report for the fiscal year 2022 at http://www.boule.com.

The annual report is available in Swedish below as a PDF and in the European Single Electronic Format (ESEF), printed copies of the Swedish version will be available to shareholders upon request by late April.

The annual report will also be made available in English at http://www.boule.com at a later date, in time for the Annual General Meeting on May 4, 2023 at the latest.

For more information, please contact:
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90
Jan Benjaminson, CFO, Boule Diagnostics AB, phone +46 (0)70-666 93 88

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com

This information is information that Boule Diagnostics AB is obliged to make public pursuant to the Securities Market Act.
The information was submitted for publication, through the agency of the contact person set out above, at 09.30 CET on April 5, 2023.

Boule Diagnostics AB Årsredovisning 2022

boule-2022-12-31-sv